Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.
Skin involvement is common in systemic lupus erythematosus (SLE), but may be resistant to conventional treatment. We sought to evaluate the efficacy of anifrolumab (ANI) in refractory cutaneous manifestations of SLE.Case series...
Read More